Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murepavadin for Ventilator-Associated Bacterial Pneumonia
NCT03409679Phase 3Terminated
- Sponsor
- Polyphor
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Modified Peptides
- Countries
- 13
01
Overview
A Phase 3 trial of murepavadin in ventilator-associated pneumonia (VAP), sponsored by Polyphor. Started Mar 2018; status: terminated.
02
Drugs
murepavadin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03409679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409679.